We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Whole-Genome Sequencing Diagnoses Early Infantile Epileptic Encephalopathy

By LabMedica International staff writers
Posted on 30 Aug 2018
Early infantile epileptic encephalopathy (EIEE) is a rare epilepsy syndrome that causes intractable seizures with multiple seizure types and presents in the first months of life. More...
While the prevalence of EIEE is unclear, and only affects a subset of all infants with seizures, infants with EIEE have serious medical complications.

EIEE patients typically exhibit developmental delay, profound intellectual impairment, and progress to severe psychomotor impairment and early death. Structural brain malformations, birth injury, and inborn errors of metabolism can cause EIEE, but once these causes are accounted for most remaining cases of EIEE are presumed to have a genetic basis.

Scientists at the University of Utah School of Medicine (Salt Lake City, UT, USA) combined deep whole-genome sequencing and a new reference-free de novo variant calling algorithm they developed and applied it to a cohort of 14 patients for whom previous testing led to no diagnosis. The team prioritized the variants they found based on whether they were missense, frameshift, or nonsense variants that fell in known EIEE genes, candidate EIEE genes, or other regions using the GEMINI framework. The team used the Illumina HiSeq X platform to sequence the 14 individuals they recruited into their study, as well both parents of each child, to an average 65X coverage.

The investigators found that for nine patients, they uncovered single, de novo variants in which they had high confidence in pathogenicity. For seven, they found de novo missense mutations affecting ion channel genes like SCNA1, SCN2A, and KCNQ2 that have known links to EIEE. In the two others, they found missense mutations affecting the EEF1A2 and PIGA genes. In two additional patients, they uncovered de novo missense of putative loss-of-function mutations in the protein-coding region of genes that hadn't before been associated with EIEE: DEAF1 and CAMK2G.

The authors concluded that whole-genome sequencing offers a number of advantages for diagnosing monogenic diseases like EIEE. One such advantage, they said is cost. Even though the cost of sequencing remains high, they noted the participants in their study had undergone, in some cases, years of diagnostics tests, each had undergone a minimum of 24 diagnostic tests, costing an average USD 30,866. Whole-genome sequencing, they concluded, could save both time and money. The study was published on August 13, 2018, in the journal npj Genomic Medicine.

Related Links:
University of Utah School of Medicine


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.